Fifth annual 'Pain in the (Supply) Chain' survey finds continuing balancing act between growth and cost control
Ever-increasing regulatory compliance issues are a top worry of supply-chain decisionmakers worldwide, according to the latest “Pain in the (Supply) Chain” survey conducted by UPS Healthcare Logistics (Atlanta). The company, which has positioned itself aggressively to provide global supply chain management services for healthcare products manufacturers, finds that 65% of respondents globally cited regulatory compliance an impact issue; the second highest issue was cost management, cited by 60%. (At the same time, only 41% of respondents felt that they were successfully addressing cost issues). Responses were gathered, by telephone interviews this spring, from 375 healthcare executives in the US, Western Europe, Asia and Latin America, representing pharma, biotech and med-device manufacturers.
UPS also provides five-year trend data of the survey. One of the more prominent results is how product security has shot up as an issue: It was a concern of only 13% of respondents in 2008, then jumped to 61% by 2011 (probably a result of the infamous 2010 Eli Lilly Enfield, CT, burglary, in which $75 million worth of product was stolen; the alleged perpetrators were arrested this year). This year, product security has dropped, but only by four percentage points; and product spoilage (especially of temperature-sensitive products) is also being cited as a concern. The survey also shows that 54% of respondents have plans for implementing serialization/e-pedigree technologies in the next 3-5 years.
About 62% of respondents say that they will be working with, or increasing their reliance on, third-party logistics service providers, and significant percentages of them will be changing their distribution channels to include direct-to-patient (8%) and direct-to-provider (20%); however, the majority (55%) plan no change from existing practices. “Healthcare companies need a new level of flexibility in their supply chains and logistics operations today,” UPS concludes. Many companies are moving to a variable cost structure in which they outsource core logistics functions and take advantage of existing third-party infrastructure, labor and technology to avoid or lessen fixed costs. This approach allows companies to enter new markets and expand globally while keeping costs down.”
The executive summary of the report is available here.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.